Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment

scientific article

Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2012PLoSO...741290C
P356DOI10.1371/JOURNAL.PONE.0041290
P932PMC publication ID3432026
P698PubMed publication ID22952580
P5875ResearchGate publication ID230805131

P50authorLaurent PapazianQ34574633
P2093author name stringDjillali Annane
Antoine Roch
Gilles Capellier
Samuel Limat
Mariette Mercier
Christophe Faisy
Claire Charpentier
Gilles Blasco
Hélène Mockly
Joel Cousson
Thibault Desmettre
P2860cites workGuidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaQ22241905
Ventilator-associated pneumoniaQ28212947
Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary reportQ33433721
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescriptionQ33912931
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trialQ34020982
When can empiric therapy for intensive care unit-acquired pneumonia be withheld or withdrawn?Q35168966
Nosocomial pneumonia: epidemiology and infection controlQ36363712
Significance Testing to Establish Equivalence between Treatments, with Special Reference to Data in the Form of 2 x 2 TablesQ36578288
Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adultsQ37029217
Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy.Q37150599
Early- and late-onset pneumonia: is this still a useful classification?Q37247789
Short course antibiotic therapy for Gram-negative hospital-acquired pneumonia in the critically ill.Q37702585
The influence of infection on hospital mortality for patients requiring > 48 h of intensive care.Q39659525
Early predictors for infection recurrence and death in patients with ventilator-associated pneumoniaQ40273432
Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumoniaQ40698893
Systematic reviews: synthesis of best evidence for clinical decisionsQ40903544
A predictive risk index for nosocomial pneumonia in the intensive care unitQ43310319
Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcomeQ43521705
Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trialQ43609282
Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study GroupQ44145974
Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumoniaQ44547515
Nosocomial Pneumonia in the Intensive Care Unit Acquired by Mechanically Ventilated versus Nonventilated PatientsQ46507066
Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumoniaQ46842546
Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteriaQ47731388
Early- and late-onset ventilator-associated pneumonia acquired in the intensive care unit: comparison of risk factors.Q47824655
Relationship of microbiologic diagnostic criteria to morbidity and mortality in patients with ventilator-associated pneumonia.Q50972762
Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.Q51643088
Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse.Q51715668
Incidence and outcome of polymicrobial ventilator-associated pneumonia.Q51717315
Impact of adherence to standard operating procedures for pneumonia on outcome of intensive care unit patients.Q51861262
Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.Q53338170
Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.Q54146487
Ventilator-Associated PneumoniaQ57237894
Biologically active products of complement and acute lung injury in patients with the sepsis syndromeQ70665611
Community-acquired pneumoniaQ72077200
Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumoniaQ73923634
The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials GroupQ77293121
Pathogens in early-onset and late-onset intensive care unit-acquired pneumoniaQ80036566
Impact of an institution-specific hospital-acquired pneumonia protocol on the appropriateness of antibiotic therapy and patient outcomesQ81515756
Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unitQ82995823
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectpneumoniaQ12192
ventilatorQ813243
P304page(s)e41290
P577publication date2012-08-31
P1433published inPLOS OneQ564954
P1476titleEarly-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment
P478volume7

Reverse relations

cites work (P2860)
Q30408712Antibiotic stewardship in the intensive care unit
Q64115391Antibiotic use practice and predictors of hospital outcome among patients with systemic bacterial infection: Identifying targets for antibiotic and health care resource stewardship
Q90086575Guidelines for Antibiotic Prescription in Intensive Care Unit
Q35004845How to approach and treat VAP in ICU patients
Q37602669Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study.
Q50606202Intra-aortic balloon pump protects against hydrostatic pulmonary oedema during peripheral venoarterial-extracorporeal membrane oxygenation.
Q36078359Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
Q26768365Pseudomonas aeruginosa ventilator-associated pneumonia management
Q52670587Resistance Trends and Treatment Options in Gram-Negative Ventilator-Associated Pneumonia.
Q57294589Short- vs long-course antibiotic therapy for pneumonia: a comparison of systematic reviews and guidelines for the SIMI Choosing Wisely Campaign
Q24187768Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults
Q47646167Shorter Versus Longer Courses of Antibiotics for Infection in Hospitalized Patients: A Systematic Review and Meta-Analysis
Q40081236To which extent can we decrease antibiotic duration in critically ill patients?
Q26862843Ventilator-associated pneumonia in the ICU
Q38271775Ventilator-associated pneumonia: present understanding and ongoing debates

Search more.